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Apnea of prematurity is a common occurrence in infants born
under the gestational age (GA) of 34 weeks. Frequent apneic
episodes may lead to decreased cerebral oxygen delivery,
thus possibly having a serious detrimental impact on the
developing brain. Treatment for apnea includes mechanical
support such as continuous positive airway pressure and/or
administration of methylxanthines. Thus, methylxanthines
(caffeine, theophylline, aminophylline) are among the most
commonly used drugs in premature infants. However, reports
on the short- and long-term safety ofmethylxanthine therapy
in premature infants have been surprisingly limited. To date,
few clinical trials reported on the long-term effect of meth-
ylxanthines, and most of these studies focused on the effect
of caffeine therapy. Compared to aminophylline, caffeine
was shown to have better long-term outcomes with lower
toxicity and no association with neurodevelopmental
disability.1 In addition, in a study of 33 preterm infants that
compared the effect of aminophylline and caffeine on cere-
bral blood flow, it was shown that as soon as 2 hours after
administration of aminophylline, global cerebral blood flow
was significantly decreased in the aminophylline group.2
While more investigations on the long-term effect of
caffeine therapy for apnea of prematurity have been pub-
lished during the past decade, reports on the effects of
aminophylline/theophylline on clinically important outcomes
such as drug safety and long-term effects on neuro-
developmental outcome are still sparse. This is of substantial
concern to many neonatologists in Taiwan and many other
countries where aminophylline/theophylline is used exten-
sively due to lackofcaffeine.The reportofDavisetal3was the
first human clinical observational study to show a possible
association between the administration of theophylline and
cerebral palsy at 14 years of age in a cohort study of 130
premature children of birth body weight of < 1501 g.
The mechanisms by which methylxanthines might induce
inadvertent cerebral damage have been disputed over past
years. Several reports suggested caution in the use of
aminophylline, because it was shown to increase cerebral
metabolic rate and decrease the rate of anoxic survival inhttp://dx.doi.org/10.1016/j.pedneo.2015.12.001
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hours of aminophylline administration, there was an
increased oxygen consumption by 20e25% in preterm in-
fants.5 Another reason that raised the concern about
aminophylline use in preterm infants is that methylxan-
thines are antagonists of adenosine receptors. Adenosine
has neuroprotective ability and plays an important role in
the mediation of local vascular regulation, and serves to
maintain a consistent oxygen uptake. Inhibition of such
regulatory ability (e.g., by aminophylline) may result in
perturbations of vascular circulation. It is therefore spec-
ulated that as an adenosine inhibitor, aminophylline may
impair the regulation of neonatal cerebral oxygenation,
resulting in potentially harmful neurological outcomes.
However, not all reports showed a detrimental effect of
aminophylline administration. Bona et al6 found that,
compared to controls, pretreatment with theophylline in 7-
day-old premature rats markedly reduced brain injury after
hypoxia-ischemia insult. As mentioned earlier, although
Davis et al3 suggested an association between cerebral
palsy and theophylline exposure, among children without
severe sequel, those who had received theophylline ach-
ieved higher psychological test scores. The study of Tey
et al7 suggested that aminophylline therapy for apnea of
prematurity had no apparent risk on the neuro-
developmental outcomes of very low birth weight infants at
corrected age of 18 months. The results of this analysis may
come as a relief for many neonatologists who still use
aminophylline extensively for the treatment of apnea of
prematurity. However, there are several limitations to this
study. First, the retrospective nature of this analysis pre-
cluded conclusive elimination of aminophylline as a risk
factor for poor neurological outcome. Second, the short
outcome follow-up at 18 months of age may not accurately
predict neurological function later in childhood. Finally,
although this study enrolled premature babies of birth body
weight of < 1500 g, the mean birth body weight (BBW) and
GA of their participants were relatively high (mean BBW:
1219 g and GA: 29 weeks). Thus, whether their result mayby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
2 Editorialbe applied to smaller premature infants with extreme low
birth body weight remains doubtful.
In conclusion, aminophylline/theophylline have been
usedextensively for the treatmentof apneaofprematurity in
Taiwan andmany other Asian countries. Since somany highly
vulnerable infants have been exposed regularly to these
methylxanthines, there is a great need formore clinical trials
with larger numbers of extremely low birth weight infants,
to demonstrate the safety of aminophylline/theophylline
treatment with respect to neurodevelopmental outcome.
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